Medicare Likely to Negotiate Prices for Obesity Drugs in Next Few Years: CBO

The Centers for Medicare and Medicaid Services is highly likely to negotiate the price for Novo Nordisk’s obesity therapy Wegovy (semaglutide) in the coming years, according to a Wednesday report from the Congressional Budget Office.